Privia Health Group (NASDAQ:PRVA) Posts Earnings Results, Beats Expectations By $0.11 EPS

Privia Health Group (NASDAQ:PRVA) issued its quarterly earnings data on Thursday. The company reported $0.19 earnings per share for the quarter, beating analysts’ consensus estimates of $0.08 by $0.11, FiscalAI reports. Privia Health Group had a return on equity of 2.81% and a net margin of 0.97%.The company had revenue of $603.85 million for the quarter, compared to the consensus estimate of $560.99 million. During the same quarter last year, the company earned $0.22 earnings per share. The firm’s revenue for the quarter was up 25.8% compared to the same quarter last year.

Here are the key takeaways from Privia Health Group’s conference call:

• Provider and attribution growth: Implemented providers reached 5,535 (+13.6% YoY) and attributed lives hit 1.6M (+26.5% YoY), driving practice collections up 14.6% to $914.8M and providing visible revenue runway for 2026.
• Profitability expansion: Adjusted EBITDA rose 36.3% to $36.7M with EBITDA representing 28.5% of care margin (up 290 bps), and management expects ~20% EBITDA growth at the midpoint of guidance with ~80% conversion to free cash flow.
• Strong balance sheet and reiterated guidance: Ended Q1 with $419.5M cash and no debt, maintained full-year 2026 guidance (raising only attributed-lives range), and signaled capacity to fund organic growth and disciplined M&A.
• M&A and integration progress: The Evolent ACO assets are reported ahead of integration schedule, management says the business-development pipeline is robust and will be used to expand Privia’s multi-state footprint.
• Technology and AI focus: New CTO hire and a push to deploy generative AI across enterprise, care-center, and care-delivery workflows are expected to boost productivity and help push margins toward the high end of long-term targets.

Privia Health Group Stock Down 3.7%

Shares of Privia Health Group stock traded down $0.90 on Friday, reaching $23.10. 1,080,445 shares of the stock were exchanged, compared to its average volume of 972,100. The business has a 50 day moving average price of $22.73 and a two-hundred day moving average price of $23.34. The firm has a market capitalization of $2.90 billion, a price-to-earnings ratio of 144.35, a PEG ratio of 1.50 and a beta of 0.96. Privia Health Group has a twelve month low of $18.77 and a twelve month high of $26.51.

Insider Activity

In related news, CFO David Mountcastle sold 1,206 shares of the company’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $25.00, for a total value of $30,150.00. Following the completion of the transaction, the chief financial officer owned 214,847 shares of the company’s stock, valued at approximately $5,371,175. This represents a 0.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Parth Mehrotra sold 26,509 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $22.11, for a total value of $586,113.99. Following the completion of the sale, the chief executive officer owned 555,443 shares of the company’s stock, valued at $12,280,844.73. This trade represents a 4.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 274,255 shares of company stock valued at $6,299,092 in the last ninety days. Insiders own 5.70% of the company’s stock.

Institutional Investors Weigh In On Privia Health Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in PRVA. Durable Capital Partners LP grew its position in shares of Privia Health Group by 1.8% in the third quarter. Durable Capital Partners LP now owns 11,691,685 shares of the company’s stock valued at $291,123,000 after purchasing an additional 203,842 shares during the period. State Street Corp raised its position in shares of Privia Health Group by 1.5% during the 2nd quarter. State Street Corp now owns 4,171,069 shares of the company’s stock worth $95,935,000 after purchasing an additional 61,853 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Privia Health Group by 6.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,264,038 shares of the company’s stock valued at $53,682,000 after buying an additional 128,415 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Privia Health Group by 2.7% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,165,355 shares of the company’s stock valued at $53,917,000 after buying an additional 55,944 shares in the last quarter. Finally, Franklin Resources Inc. boosted its holdings in Privia Health Group by 19.1% in the 3rd quarter. Franklin Resources Inc. now owns 1,596,634 shares of the company’s stock worth $39,756,000 after buying an additional 256,236 shares during the last quarter. Hedge funds and other institutional investors own 94.48% of the company’s stock.

Privia Health Group News Summary

Here are the key news stories impacting Privia Health Group this week:

• Positive Sentiment: Privia Health reported first-quarter results that beat revenue expectations, with sales of $603.85 million versus the $560.99 million estimate, and EPS of $0.19 versus $0.08 expected. The company also said revenue rose 25.8% year over year, and it reiterated full-year 2026 guidance. Article Title
• Positive Sentiment: The company’s updated 2026 outlook calls for revenue of $2.4 billion to $2.5 billion, which is in line with or slightly above market expectations and supports the case for continued growth. Article Title
• Neutral Sentiment: Investors are also parsing the Q1 2026 earnings call transcript and related earnings coverage for management commentary on margins, utilization trends, and the path to hitting full-year targets. Article Title
• Negative Sentiment: Two insider-selling reports may be weighing on sentiment: the CFO sold about $179,690 of stock and a director sold about $427,229 of stock, which can signal caution even when fundamentals are improving. Article Title Article Title

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Royal Bank Of Canada initiated coverage on shares of Privia Health Group in a research note on Friday, January 9th. They set an “outperform” rating and a $31.00 price objective for the company. Canaccord Genuity Group lowered their target price on shares of Privia Health Group from $35.00 to $34.00 and set a “buy” rating for the company in a research note on Friday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Privia Health Group in a report on Friday, March 27th. Truist Financial upped their price target on Privia Health Group from $31.00 to $33.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Finally, Barclays raised their price objective on Privia Health Group from $23.00 to $25.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 25th. Eleven research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $31.23.

Privia Health Group Company Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.